Changes from baseline in (a) severity of ARDS according to Berlin Criteria, (b) Clinical Improvement Scale, and (c) serum levels of inflammatory markers (CRP, IL-6, IL-8, and TNF-α) will be used for the evaluation of MSC-based therapeutic effects. This evidence concerns the gene IL6 and acute respiratory distress syndrome.